Guiyang Xintian Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 4.1% above its 200 day moving average.

From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.

Guiyang Xintian Pharmaceutical Co.,Ltd's total revenue rose by 6.5% to $239M since the same quarter in the previous year.

Its net income has increased by 3.7% to $36M since the same quarter in the previous year.

Finally, its free cash flow grew by 151.1% to $28M since the same quarter in the previous year.

Based on the above factors, Guiyang Xintian Pharmaceutical Co.,Ltd gets an overall score of 5/5.